专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20090081702A1 DISCRIMINATON OF CARDIAC DYSFUNCTION IN PREGNANT FEMALES 审中-公开
标题翻译：心脏功能障碍在怀孕中的辨别
公开(公告)号：US20090081702A1
公开(公告)日：2009-03-26
申请号：US11856842
申请日：2007-09-18
申请人： GEORG HESS , ANDREA HORSCH , DIETMAR ZDUNEK
发明人： GEORG HESS , ANDREA HORSCH , DIETMAR ZDUNEK
IPC分类号： G01N33/566 , G01N33/573
CPC分类号： G01N33/6893 , G01N2800/32 , G01N2800/368
摘要： The present invention relates to a method for diagnosing if a pregnant woman suffers from a cardiac dysfunction, comprising the steps of a) measuring the level of a natriuretic peptide in a sample b) measuring the level of placental growth factor and/or sFlt-1 or a variant thereof in a sample, wherein an increased level of a natriuretic peptide and a decreased level of placental growth factor and/or an increased level of sFlt-1 or a variant thereof indicates the presence of a placenta-associated cardiac dysfunction, and wherein an increased level of a natriuretic peptide and a not decreased level of placental growth factor and/or a not increased level of sFlt-1 or a variant thereof indicates the presence of a cardiac dysfunction related to heart disease. The present invention also relates to an array, to an immunological rapid test, to the use of corresponding kits, and to methods for a decision support for the possible treatment of a pregnant woman suffering from a cardiac dysfunction.
摘要翻译：本发明涉及一种用于诊断孕妇是否患有心脏功能障碍的方法，包括以下步骤：a）测量样品中利尿钠肽的水平b）测量胎盘生长因子和/或sFlt-1的水平或其变体，其中增加的利尿钠肽水平和胎盘生长因子水平降低和/或sFlt-1或其变体水平升高表明胎盘相关心脏功能障碍的存在，以及其中增加的利钠肽水平和胎盘生长因子水平不降低和/或sFlt-1或其变体的不增加水平表明存在与心脏病相关的心脏功能障碍。本发明还涉及免疫学快速测试的阵列，使用相应的试剂盒，以及用于对患有心脏功能障碍的孕妇进行可能治疗的决定支持的方法。

52. 发明授权

US08663941B2 Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction 有权
标题翻译：诊断和监测急性胸痛和无心肌梗死患者心脏缺血的方法
公开(公告)号：US08663941B2
公开(公告)日：2014-03-04
申请号：US13480452
申请日：2012-05-24
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/573
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/4753 , G01N2333/71 , G01N2800/324
摘要： The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein.
摘要翻译：本公开涉及一种用于诊断患有急性冠状动脉综合征患者的缺血状态的方法，该方法不能满足心肌梗死的诊断标准。本公开还涉及用于鉴定易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，但不满足心肌梗死的诊断标准。本公开的方法基于所述受试者样品中fms样酪氨酸激酶-1（sFLT-1）和任选的肝细胞生长因子（HGF）的测定。本公开还涉及用于实施本文公开的方法的试剂盒和/或装置。

53. 发明申请

US20120028292A1 METHODS FOR DIAGNOSING KIDNEY DAMAGE ASSOCIATED WITH HEART FAILURE 审中-公开
标题翻译：用于诊断与心脏衰竭相关的KIDNEY损伤的方法
公开(公告)号：US20120028292A1
公开(公告)日：2012-02-02
申请号：US13267981
申请日：2011-10-07
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C12Q1/02 , C12M1/34 , G01N30/00 , G01N33/53
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2800/325 , G01N2800/347
摘要： Disclosed is a method for diagnosing kidney damage in a subject suffering from heart failure including the steps of a) determining the amounts of liver-type fatty acid binding protein (L-FABP) and kidney injury molecule 1 (KIM-1) and optionally a natriuretic peptide in a sample of a subject, b) forming the L-FABP/KIM-1 ratio, c) comparing the amounts determined in step a) with reference amounts, and diagnosing the kidney damage. Also disclosed are a device and a kit for carrying out the method.
摘要翻译：公开了一种用于诊断患有心力衰竭的受试者的肾损伤的方法，包括以下步骤：a）确定肝型脂肪酸结合蛋白（L-FABP）和肾损伤分子1（KIM-1）的量，以及任选地利钠肽在受试者样品中，b）形成L-FABP / KIM-1比例，c）将步骤a）中测定的量与参考量进行比较，并诊断肾损伤。还公开了用于执行该方法的装置和套件。

54. 发明申请

US20110263443A1 DIFFERENTIATING BETWEEN FIBROSIS AND CIRRHOSIS 审中-公开
标题翻译：差异与血栓形成之间的差异
公开(公告)号：US20110263443A1
公开(公告)日：2011-10-27
申请号：US13174839
申请日：2011-07-01
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C40B30/00 , C40B40/10 , C40B60/12
CPC分类号： G01N33/6863 , G01N33/6872 , G01N2333/495 , G01N2333/52 , G01N2333/70596 , G01N2800/085
摘要： The present invention is concerned with a method for differentiating between liver fibrosis and liver cirrhosis in a subject based on the determination of growth differentiation factor 15 (GDF-15), hepatocyte growth factor (HGF) and/or endoglin in a sample of a subject and comparing the thus determined amount with a reference amount (reference amounts). Further envisaged by the present invention are kit and a device adapted to carry out the method of the present invention.
摘要翻译：本发明涉及基于受试者样品中生长分化因子15（GDF-15），肝细胞生长因子（HGF）和/或内皮糖蛋白的测定来区分受试者的肝纤维化和肝硬化的方法。并将如此确定的量与参考量（参考量）进行比较。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。

55. 发明申请

US20110113864A1 IDENTIFICATION OF SUBJECTS BEING SUSCEPTIBLE TO ANTI-ANGIOGENESIS THERAPY 有权
标题翻译：鉴定出抗生素治疗无效的病人
公开(公告)号：US20110113864A1
公开(公告)日：2011-05-19
申请号：US13010183
申请日：2011-01-20
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/48
CPC分类号： G01N33/6887 , A61P35/00 , C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , G01N33/53 , G01N2333/4712 , G01N2333/58 , G01N2800/32 , G01N2800/52
摘要： The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于鉴定受抗体血管生成治疗敏感的受试者的方法，其基于确定受试者样品中心肌肌钙蛋白的量并将该量与合适的参考量进行比较。本发明还包括适用于实施本发明方法的试剂盒和装置。

56. 发明申请

US20110081671A1 VASCULAR MARKERS IN THE REMODELING OF CARDIAC INJURY 审中-公开
标题翻译：血管紧张素受体在心脏重塑中的作用
公开(公告)号：US20110081671A1
公开(公告)日：2011-04-07
申请号：US12719914
申请日：2010-03-09
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C12Q1/48 , C12M1/34
CPC分类号： G01N33/6893 , G01N2333/71 , G01N2800/324
摘要： The present invention is concerned with diagnostic means and methods. More specifically, the present invention relates to a method for diagnosing the angiogenic status of a subject suffering from myocardial infarction comprising determining the amounts of P1GF, sFLT1 and endoglin in a first sample of a subject obtained after myocardial infarction and in a second sample of the subject obtained after the first sample and comparing the amounts in the first sample with those in the second sample whereby the angiogenic status is diagnosed. The present invention also encompasses a method of determining whether a subject suffering from myocardial infarction is susceptible to a pro-angiogenic therapy. Finally, the present invention relates to a kit or a device for carrying out the method of the invention.
摘要翻译：本发明涉及诊断手段和方法。更具体地，本发明涉及用于诊断患有心肌梗死的受试者的血管生成状态的方法，包括测定在心肌梗塞后获得的受试者的第一样品中的P1GF，sFLT1和内皮糖蛋白的量，以及在第一个样品之后获得的受试者，并将第一个样品中的量与第二个样品中的量进行比较，从而诊断血管生成状态。本发明还包括确定患有心肌梗死的受试者是否易于进行促血管生成治疗的方法。最后，本发明涉及一种用于实施本发明方法的试剂盒或装置。

57. 发明申请

US20110059540A1 IDENTIFYING SUSCEPTIBILITY OF A SUBJECT TO CARDIAC THERAPY BASED ON DETERMINATION OF A CARDIAC TROPONIN, SCD40L, AND C-REACTIVE PROTEIN 审中-公开
标题翻译：基于确定CARDIAC TROPONIN，SCD40L和C反应蛋白的心脏病治疗方面的突出特征
公开(公告)号：US20110059540A1
公开(公告)日：2011-03-10
申请号：US12944833
申请日：2010-11-12
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/53 , G01N33/00 , B01L3/00
CPC分类号： G01N33/5091 , G01N2333/4712 , G01N2800/324
摘要： Disclosed is a method for identifying a subject being susceptible to a cardiac therapy based on determination of a cardiac troponin T and the additional determination of C-reactive protein (CRP) or sCD40L (soluble CD40 ligand) in a sample of a subject with stable coronary heart disease and a history of an acute cardiovascular event. Also disclosed is a method for predicting the risk of mortality and/or a further acute cardiovascular event for a subject with stable coronary heart disease and a history of acute cardiovascular event based on the determination of the aforementioned markers. Further disclosed are kits and devices adapted to carry out the disclosed methods.
摘要翻译：公开了一种基于心肌肌钙蛋白T的测定以及具有稳定冠状动脉的受试者样品中C-反应蛋白（CRP）或sCD40L（可溶性CD40配体）的额外测定来识别对心脏治疗敏感的受试者的方法。心脏病和急性心血管事件的病史。还公开了一种用于基于上述标记物的测定预测具有稳定性冠心病和急性心血管事件病史的受试者的死亡风险和/或进一步急性心血管事件的方法。进一步公开的是适用于实施所公开方法的套件和装置。

58. 发明申请

US20110053191A1 METHOD FOR RISK REDUCTION IN GLYCEMIC CONTROL 审中-公开
标题翻译：降低血糖控制风险的方法
公开(公告)号：US20110053191A1
公开(公告)日：2011-03-03
申请号：US12938430
申请日：2010-11-03
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/68 , C12M1/34
CPC分类号： G01N33/689 , G01N33/6893 , G01N2333/471 , G01N2333/475 , G01N2800/042
摘要： Disclosed is a method for identifying a subject being susceptible to a therapy for intensive glycemic control, the subject suffering from diabetes and being in need for a therapy for intensive glycemic control, based on determining the amount of PLGF (placental growth factor) in a sample of the subject and comparing the thus determined amount to a reference amount. In a preferred embodiment, the method further includes determining at least one further marker selected from the group consisting of a cardiac troponin and a natriuretic peptide and comparing the determined amount(s) to a reference amount (amounts). Moreover, disclosed is a method for predicting the risk of an acute cardiovascular event in a subject who suffers from diabetes and is on intensive glycemic control. Further disclosed is a kit and a device adapted to carry out the method of the present invention.
摘要翻译：公开了一种基于确定样品中PLGF（胎盘生长因子）的量来鉴定易于进行强化血糖控制的治疗对象，患有糖尿病并且需要进行强化血糖控制治疗的受试者的方法并将如此确定的量与参考量进行比较。在优选的实施方案中，所述方法还包括确定选自心肌肌钙蛋白和利尿钠肽的至少一种另外的标志物，并将测定的量与参考量（量）进行比较。此外，公开了一种用于预测患有糖尿病并且正在进行强化血糖控制的受试者中急性心血管事件的风险的方法。进一步公开的是适用于实施本发明方法的套件和装置。

59. 发明申请

US20110033886A1 GDF-15 AS BIOMARKER IN TYPE 1 DIABETES 审中-公开
标题翻译： GDF-15作为1型糖尿病生物标志物
公开(公告)号：US20110033886A1
公开(公告)日：2011-02-10
申请号：US12908987
申请日：2010-10-21
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C12Q1/02 , C12M1/34
CPC分类号： G01N33/6863 , G01N2333/495 , G01N2800/042 , G01N2800/347
摘要： The present invention relates to a method of predicting if a diabetes type 1 patient will suffer from one or more complications selected from cardiovascular complications, terminal renal failure, and death, the method including (a) determining the amount of GDF-15 in a sample of a diabetes type 1 patient; and (b) comparing the amount of GDF-15 determined in step (a) to a reference amount and establishing a prediction. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.
摘要翻译：本发明涉及一种预测1型糖尿病患者是否会患有从心血管并发症，终末期肾衰竭和死亡中选择的一种或多种并发症的方法，该方法包括（a）测定样品中GDF-15的量的1型糖尿病患者; 和（b）将步骤（a）中确定的GDF-15的量与参考量进行比较并建立预测。本发明还包括用于实施上述方法的装置和试剂盒。

60. 发明申请

US20100255594A1 NT-PROBNP/TROPONIN RATIO FOR ASSESSING MYOCARDIAL DYSFUNCTION 失效
标题翻译： NT-PROBNP / TROPONIN比例评估心肌梗死
公开(公告)号：US20100255594A1
公开(公告)日：2010-10-07
申请号：US12748879
申请日：2010-03-29
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , G01N33/5302 , G01N33/6887 , G01N33/6893 , G01N2333/58 , G01N2800/325
摘要： The present invention relates to a method of diagnosing if a subject which has suffered from an acute myocardial infarction is also suffering from a pre-existing myocardial dysfunction, the method comprising a) determining the amount of a natriuretic peptide in a sample of the subject; b) determining the amount of a cardiac troponin in a sample of the subject; c) calculating the ratio (natriuretic peptide/cardiac troponin); and d) diagnosing if the elevated natriuretic peptide level is related to a preexisting myocardial dysfunction or if the elevated level is caused by the acute myocardial infarction, based on the ratio calculated in step c). The method allows determining whether the individual has suffered from a myocardial dysfunction, in particular heart failure, before the myocardial infarction has occurred.
摘要翻译：本发明涉及一种诊断是否患有急性心肌梗死的受试者也患有预先存在的心肌功能障碍的方法，所述方法包括：a）确定受试者样品中利尿钠肽的量; b）确定受试者样品中心肌肌钙蛋白的量; c）计算比例（利钠肽/心肌肌钙蛋白）; 以及d）基于在步骤c）中计算的比率来诊断升高的利尿钠肽水平是否与预先存在的心肌功能障碍相关，或者如果升高的水平是由急性心肌梗死引起的。该方法允许在发生心肌梗死之前确定个体是否患有心肌功能障碍，特别是心力衰竭。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式